This session will cover non-randomized studies are increasingly recognized as a source of insights into the real-world performance of novel therapeutic products, particularly when traditional RCTs are impractical or lack generalisability. However, so far, the lack of methodological frameworks to guide the trustworthy integration and evidence synthesis from RCTs and NRS has hindered their acceptance in decision making.